A retrospective study of patients with chronic hepatitis C virus (HCV) infection who were administered elbasvir/grazoprevir (ZEPATIER) in the US Department of Veterans Affairs (VA) healthcare system

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 02 Dec 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Nov 2018 Results assessing utilization and real-world effectiveness with EBR/GZR-containing regimens by treatment duration among participants with HCV GT1b (n=3440), presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases
26 Apr 2017 New trial record
21 Apr 2017 Results (n=2436) from this trial were presented at the The International Liver Congress 2017, according to a Merck and Co. media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com